(1)
Circulating cell-free mRNA in blood reflective of NAFLD/NASH liver pathology
PALO ALTO, Calif., Feb. 23, 2021 /PRNewswire/ Molecular Stethoscope, Inc., a precision medicine biotechnology company, announces publication of its human proof-of-concept study describing the stratification of NAFLD/NASH patients with clinically relevant and advanced liver fibrosis using the company s Next-Generation cell-free mRNA Liquid Biopsy Technology Platform. The study titled Non-invasive Stratification of Non-Alcoholic Fatty Liver Disease by Whole-transcriptome Cell-free mRNA Characterization was published in the
American Journal of Physiology -
Gastrointestinal and Liver Physiology, a journal of the American Physiological Society. The first author is Naga Chalasani, M.D., Professor of Gastroenterology and Hepatology and Interim Chair in the Department of Medicine at Indiana University in the USA. Dr. Chalasani is the leading author of the AASLD Practice Guidelines for the diagnosis and
India comes out first to identify need for action for NAFLD biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Centre launches operational guidelines for critical illnesses including cancer, diabetes
Centre launches operational guidelines for critical illnesses including cancer, diabetes
File Photo
NEW DELHI: Union Minister of Health and Family Welfare Dr Harsh Vardhan launched the operational guidelines for Integration of NAFLD (Non-Alcoholic Fatty Liver Disease) with NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke), here on Monday.
Expressing his elation at the timely importance of the event, Harsh Vardhan said, “NAFLD, the abnormal accumulation of fat in the liver in the absence of secondary causes of fatty liver, such as harmful alcohol use, viral hepatitis, or medications is a serious health concern as it encompasses a spectrum of liver abnormalities, from a simple non-alcoholic fatty liver (NAFL, simple fatty liver disease) to more advanced ones like non-alcoholic steatohepatitis (NASH), cirrhosis and even liver cancer
New Delhi [India], February 22 (ANI): People who are overweight and have diabetes are at a higher risk of developing the non-alcoholic fatty liver disease as the prevalence of NAFLD is around 9 percent to 32 percent in the Indian population, the Union Health Ministry informed on Monday.
Operational guidelines launched for integration of Non-Alcoholic Fatty Liver Disease with NPCDCS
SECTIONS
Last Updated: Feb 22, 2021, 04:42 PM IST
Share
Synopsis Over the last two decades global burden of NASH has more than doubled. Globally, NASH caused 40 lakh prevalent cases of compensated cirrhosis in 1990, which increased to 94 lakh cases in 2017. NAFLD is emerging as an important cause of liver disease in India, Vardhan was quoted as saying in a Health Ministry statement.
ANI
Researchers have found NAFLD in 40 to 80 per cent of people who have type 2 diabetes and in 30 to 90 per cent of people who are obese, he said.
Underscoring the importance of tackling NAFLD (Non-Alcoholic Fatty Liver Disease) as a step to deal with the country s burden of non-communicable diseases, Health Minister Harsh Vardhan on Monday launched the operational guidelines for Integration of NAFLD with NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disea